Tests Drugs on a Tumor That's Still in the Body
January 16, 2013 | MIT Technology Review
Presage’s device would allow oncologists to test potentially harmful compounds in tiny amounts before giving patients a full dose.
Comparing combos quickly
May 7, 2012 | BioCentury
Millennium Pharmaceuticals Inc. is using an in vivoscreening platform from Presage Biosciences Inc. to speed up its preclinical characterization of can-cer combination therapies. The platform enables simultaneous comparison of up tofour treatments within a single tumor in a live mouse and could better predict effi-cacy than the in vitro assays that usually precede large-scale animal studies.
Looks to Help Millennium Pick Cancer Drug Winners Early
April 6, 2012 | xconomy.com
Seattle-based Presage Biosciences, a spinoff from the Fred Hutchinson Cancer Research Center, is looking to help cancer drugmakers separate the winning compounds from the losers early in development, and now it’s found a major partner to put this idea to the test.
Millennium gets use of Presage drug combo technology
April 6, 2012 | Mass High Tech
Millennium: The Takeda Oncology Company has entered into a cancer research agreement with Presage Biosciences of Seattle, Wash., that gives the Cambridge biopharmaceutical company access to Presage’s technology for non-clinical identification of novel oncology drug combinations in solid tumors.
Presage Biosciences, Millennium to Partner on Cancer Drugs
April 6, 2012 | Science Business
Presage Biosciences, a biotechnology company in Seattle, and Millenium, a division of Takeda Pharmaceuticals in Cambridge, Massachusetts, say the two companies will collaborate on the development of new cancer therapies. Financial terms of the agreement were not disclosed.
Presage, a Hutch Spinoff, Raises $3M From Angels to Boost Cancer Drug Hit Rate
March 16, 2010 | xconomy.com
Seattle-based Presage Biosciences has a big dream for a biotech startup—and now it has seed capital to put that dream to the test...